0.000
0.00 (0.00%)
| Price / Sales | 14.62 |
| Price / Book | 24.41 |
| Profit Margin | -27.70% |
| Operating Margin (TTM) | -27.50% |
| Diluted EPS (TTM) | -2.51 |
| Quarterly Revenue Growth (YOY) | 55.50% |
| Quarterly Earnings Growth (YOY) | -99.40% |
| Total Debt/Equity (MRQ) | 208.50% |
| Current Ratio (MRQ) | 2.80 |
| Operating Cash Flow (TTM) | -145.55 M |
| Levered Free Cash Flow (TTM) | -20.78 M |
| Return on Assets (TTM) | -9.75% |
| Return on Equity (TTM) | -47.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Blueprint Medicines Corporation | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Average | 1.00 |
|
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.88% |
| % Held by Institutions | 109.19% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |